Peptide Profile

Semax

Synthetic ACTH Analog

Off Label10 sourcesShop Semax

Overview

Composition

Synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) analog of the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10), with an added C-terminal Pro-Gly-Pro sequence for enhanced stability and duration of action

Mechanism of Action

Lacks the hormonal activity of native ACTH but is studied for nootropic, neuroprotective, and neurotrophic effects through BDNF/TrkB signaling, monoamine pathways, oxidative-stress modulation, inflammatory signaling, and neuronal survival pathways

Primary Effects

Explored for cognition, attention, ischemic-injury recovery, and neuroprotection, with most human evidence coming from Russian clinical literature.

Discovery & Background

Developed in the 1980s–1990s by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences, building on studies of ACTH fragments for neurotrophic effects without endocrine activity

Initially designed to address ischemic brain conditions like stroke and traumatic injury, with early work highlighting its ability to enhance memory, attention, and neuronal resilience; approved in Russia for specific neurological indications (e.g., stroke, cognitive disorders, optic nerve disease)

Approved in Russia for specific neurological indications; investigational outside Russia and lacks approval by bodies like the FDA or EMA

Research Overview

Preclinical studies (rodent models of ischemia, hypoxia, Alzheimer's-like pathology, Parkinson's models) show Semax reduces infarct size, promotes neuronal survival, upregulates BDNF/TrkB expression, modulates gene expression related to immune/vascular systems, and improves cognitive performance

01
Human data include Russian clinical trials and small pilots reporting outcomes in ischemic stroke such as recovery markers and BDNF changes
02
Small healthy-volunteer studies report attention, memory, and EEG changes
03
Potential in optic nerve disease or stress-related conditions
04
Evidence for nootropic effects in healthy individuals is limited to small studies
05
Neuroprotective benefits appear strongest in acute neurological insults
06
Large-scale international trials are scarce, and long-term human data remain limited

Not approved for broad therapeutic use outside Russia

Safety Considerations

Monitoring

Cognitive function
Mood and anxiety levels
Neurological symptoms
Overall mental clarity
Sleep and overstimulation symptoms

Side Effects

Common

Generally well-tolerated
Mild local irritation has been reported
Rare headaches or overstimulation
Minimal reports of serious issues

Contraindications

Limited data; caution in neurological conditions without oversight
Not approved for therapeutic use outside Russia
Evidence outside Russia is limited to small studies and preclinical models

Educational Notice

Semax has preclinical and Russian clinical literature for neuroprotection and cognition-related endpoints, but evidence outside Russia is limited and it lacks FDA or EMA approval. The strongest teaching frame is regional clinical history plus mechanism, not broad nootropic claims. Clinical decisions require qualified medical oversight.

References